These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34047473)

  • 1. A novel signature based on pairwise PD-1/PD-L1 signaling pathway genes for predicting the overall survival in patients with hepatocellular carcinoma.
    Zhao E; Chen S; Dang Y
    Clin Transl Med; 2021 May; 11(5):e431. PubMed ID: 34047473
    [No Abstract]   [Full Text] [Related]  

  • 2. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.
    Long J; Qu T; Pan XF; Tang X; Wan HH; Qiu P; Xu YH
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1188-S1192. PubMed ID: 30539869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.
    Wang BJ; Bao JJ; Wang JZ; Wang Y; Jiang M; Xing MY; Zhang WG; Qi JY; Roggendorf M; Lu MJ; Yang DL
    World J Gastroenterol; 2011 Jul; 17(28):3322-9. PubMed ID: 21876620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
    Yasuoka H; Asai A; Ohama H; Tsuchimoto Y; Fukunishi S; Higuchi K
    Sci Rep; 2020 Jun; 10(1):10377. PubMed ID: 32587357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions.
    Liu L; Yang M; Xu Q; Zhou M; Cheng Y; Xu H; Qin Y; Liu B
    Immunotherapy; 2021 Feb; 13(2):113-123. PubMed ID: 33076728
    [No Abstract]   [Full Text] [Related]  

  • 8. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma.
    Ju F; Wang D; Huang L; Jiang C; Gao C; Xiong C; Zhai G
    Front Immunol; 2023; 14():1227756. PubMed ID: 37545535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
    Kan G; Dong W
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3063-71. PubMed ID: 26367730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
    Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
    J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward.
    Pal SK; Singh P; Vogelzang NJ
    Clin Genitourin Cancer; 2015 Aug; 13(4):257-260. PubMed ID: 25160519
    [No Abstract]   [Full Text] [Related]  

  • 13. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
    Mou H; Yang QA; Yu L; Wang T; Liu K; Shen R; Pan X; Dai Y; Wan Q; Zhou F; Qian L; Chen D; Yau T; Dong X; Wang X; Wang S
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2601-2609. PubMed ID: 33656759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-derived PD1 and PD-L1 could promote hepatocellular carcinoma growth through autophagy induction in vitro.
    Chen Z; Liu S; Xie P; Zhang B; Yu M; Yan J; Jin L; Zhang W; Zhou B; Li X; Xiao Y; Xu Y; Ye Q; Li H; Guo L
    Biochem Biophys Res Commun; 2022 May; 605():82-89. PubMed ID: 35316767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
    Zou W; Wolchok JD; Chen L
    Sci Transl Med; 2016 Mar; 8(328):328rv4. PubMed ID: 26936508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.
    Wu K; Kryczek I; Chen L; Zou W; Welling TH
    Cancer Res; 2009 Oct; 69(20):8067-75. PubMed ID: 19826049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.
    Lv T; Xiong X; Yan W; Liu M; Xu H; He Q
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spore Oil enhances the effect of cyclophosphamide inhibiting programmed death-1 and prolongs the survival of H22 tumor-bearing mice.
    Zhaojian J; Hongfei C; Cheng Y; Lin C; Wendong XU; Yaming H; Qin Z; Jing LI; Qin W; Juyan L
    J Tradit Chin Med; 2024 Aug; 44(4):652-659. PubMed ID: 39066525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
    Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
    Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.